biotech

clinical trials

Gilead Earnings Trip Over Both the Top and Bottom Lines

Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared ...
Read Full Story »
cancer

Oncobiologics Announces Potential Pricing for IPO

Oncobiologics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 5 million shares within ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Test tubes

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

All sectors of the market tend to have times of the year that are better than others, and biotechnology is no different. Typically each year, the first quarter is the ...
Read Full Story »
Female patient on gurney

Why Key Analyst Sees Huge Upside in Sarepta Therapeutics

Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw its shares get crushed on Thursday and then explode on Friday following the U.S. Food and Drug Administration (FDA) view on its Duchenne muscular ...
Read Full Story »
hospital entrance

Can BioMarin Make Treating Hemophilia More Affordable?

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ready to break above the $1 billion revenue barrier in 2016. This is a feat that marks a major hurdle for many biotech and emerging ...
Read Full Story »
FDA_logo

Cara Therapeutics Rises on FDA Judgment

Cara Therapeutics Inc. (NASDAQ: CARA) saw its shares jump early on Wednesday after the U.S. Food and Drug Administration (FDA) made a favorable judgment for them. The company announced that ...
Read Full Story »
clinical trials

Gemphire Therapeutics Gears Up for IPO

Gemphire Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but the ...
Read Full Story »
white pills

Biotech and Pharmaceuticals Highlight Jefferies Top Growth Stock Buys

With earnings season hitting its stride this week, many investors are looking to see how the companies they own perform. Two areas that have lagged all year long are biotech ...
Read Full Story »
FDA_logo

Are Analysts Realistic on Clovis Oncology Now?

Clovis Oncology Inc. (NASDAQ: CLVS) was down about 5% Tuesday and was down even more Wednesday after the Oncologic Drugs Advisory Committee voted against its lung cancer drug. The committee ...
Read Full Story »
clinical trials

Is PTC Therapeutics on the Road to Recovery?

PTC Therapeutics Inc. (NASDAQ: PTCT) saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment. The company announced that the National Institute for ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
IPO

Viamet Pharmaceuticals Files for IPO

Viamet Pharmaceuticals has registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing, but the ...
Read Full Story »
biotech word cloud

4 Key Biopharma Movers of the Past Week

Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The ...
Read Full Story »
investing

3 Stocks With Catalysts That Could Capitalize on Biotech Momentum

Biotechnology is on the move. A familiar bull market pattern since 2008 may be about to reestablish itself. That is, the S&P 500 is moving higher, outpaced by the Nasdaq, ...
Read Full Story »